huntingtons disease - RSS Feed Directory

abortion
acid reflux
adhd
alcohol treatment
allergy
alternative medicine
alzheimers dimentia
anxiety phobia
arthritis
asthma respiratory
autism
bacteria viral
biochemistry biology
bipolar
bird flu avian flu
blood hematology
body aches
breast cancer
cancer oncology
cardiovascular cardiology
cholesterol
cleft palate
clinical drug trials
colorectal cancer
compliance
cosmetic plastic surgery
cystic fibrosis
dentistry
depression
dermatology
diabetes
disaster aid
dyslexia
ear nose throat
endocrinology
epilepsy
erectile dysfunction premature ejaculation
eye health opthamology
fertility
fitness obesity
flu sars
gastrointestinal
genetics
gout
headlines
health insurance
hearing deafness
hiv aids
homecare caregivers
huntingtons disease
hypertension
immune system
internet
irritable bowel syndrome
liver disease hepatitis
lung cancer
lupus
lymphoma leukemia
mad cow disease
medical conference
medical devices
medical malpractice
medical students
medicare medicaid
mens health
mental health
migraine headache
mri pet scan
mrsa super bug
multiple sclerosis
muscular dystrophy
neurology neuroscience
nursing
nutrition agriculture
organ transplants donation
orthopaedics
pain
parkinsons disease
pediatrics
pharmaceutical industry
pregnancy
primary care
prostrate
psychology psychiatry
public health
radiology
rehabilitation
schizophrenia
senior aging
sleep disorders
smoking
sports medicine
statins
stds sexual health
stem cell research
stroke
terrorism
tropical diseases
ulcerative colitis crohns disease
urology nephrology
veterinary
water quality
womens health obgyn

feed contents

Using Lasers To Destroy Amyloid Proteins
Researchers have found that a technique used to visualize amyloid fibers in the laboratory might have the potential to destroy them in the clinic. The technique involves zapping the fluorescently-tagged fibers with a laser, which can inhibit their growth and degrade them. This study, appearing in this week's JBC, may offer a non-drug alternative to treat amyloid-based disorders like Alzheimer, Parkinson, and Huntington diseases.
medicalnewstoday.com

Clioquinol Inhibits Action Of The CLK1 Aging Gene, May Alleviate Alzheimer's
Recent animal studies have shown that clioquinol - an 80-year old drug once used to treat diarrhea and other gastrointestinal disorders - can reverse the progression of Alzheimer's, Parkinson's and Huntington's diseases. Scientists, however, had a variety of theories to attempt to explain how a single compound could have such similar effects on three unrelated neurodegenerative disorders.
medicalnewstoday.com

Brain Deletion Of FK506-Binding Protein Enhances Repetitive Behaviors In Mice
A new study reveals a link between dysregulation of a common signaling pathway and repetitive behaviors similar to those associated with multiple neurological and neurodegenerative disorders including, autism spectrum disorders, obsessive compulsive disorder, schizophrenia, and Huntington's disease.
medicalnewstoday.com

Participants In Clinical Trials Should Be Viewed As Partners In Research
While an estimated 2.3 million people in the United States take part in clinical trials every year, there currently exists no formal requirement to inform them of study results, an oversight that leaves participants confused, frustrated, and, in some cases, lacking information that may be important to their health.
medicalnewstoday.com

Novel Histone Demethylase Protein Complex Discovered By Researchers At Stowers Institute's Workman Lab
The Stowers Institute's Workman Lab has discovered a novel histone demethylase protein complex characterized in work published in Molecular Cell. The Histone H3 protein is an important component of chromatin, the packing material wrapping up chromosomal DNA and preventing unwanted transcription of the message encoded in the DNA. Histone H3 can be altered by adding (methylating) or removing (demethylating) methyl groups from the histone protein.
medicalnewstoday.com

Cambridge Laboratories Announces Launch Of XENAZINE(R) (Tetrabenazine) In The US
Cambridge Laboratories Group Limited ("Cambridge"), the privately-owned specialty pharmaceutical company, today announces that XENAZINE(R) (tetrabenazine), the first and only product approved for the treatment of chorea associated with Huntington's disease, has been launched in the US.
medicalnewstoday.com

'Deranged Calcium Signaling' Contributes To Neurological Disorder, UT Southwestern Researchers Find
Defective calcium metabolism in nerve cells may play a major role in a fatal genetic neurological disorder that resembles Huntington's disease, researchers at UT Southwestern Medical Center have found in a mouse study. The disease, called spinocerebellar ataxia 3 - also known as SCA3, or Machado-Joseph disease - is a genetic disorder that, like Huntington's, impairs coordination, speech, and vision and causes brain atrophy.
medicalnewstoday.com

Chorea Associated With Huntington's Disease Ovation - Nationwide Availability Of Xenazine (tetrabenazine) Tablets In U.S.
OVATION Pharmaceuticals, Inc. announced today that Xenazine* (tetrabenazine) Tablets, an orphan drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's disease (HD), is now available throughout the United States. Xenazine is the first and only FDA-approved treatment specifically developed for any HD-related symptom.
medicalnewstoday.com

New Clue Emerges For Cellular Damage In Huntington's Disease
"Huntington's disease presents an ideal vantage point to study neurodegenerative disease, because we know the misfolded protein that's responsible," says Martin Duennwald, formerly a postdoctoral researcher in the lab of Whitehead Member Susan Lindquist. "But we don't understand how this protein causes cellular damage and death for the neurons that are affected.
medicalnewstoday.com

Raptor Pharmaceuticals To Collaborate With Centre Hospitalier Universitaire D'Angers For Phase II Clinical Trial In Huntington's Disease
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in a Phase II clinical trial in patients with Huntington's Disease ("Huntington's").
medicalnewstoday.com

2008 Horwitz Prize Awarded To Arthur Horwich & Ulrich Hartl For Cellular Protein Folding
Columbia University will award the 2008 Louisa Gross Horwitz Prize to F. Ulrich Hartl, M.D., professor and director of the Department of Cellular Biochemistry at the Max Planck Institute of Biochemistry in Germany, and Arthur Horwich, M.D.
medicalnewstoday.com

Antioxidants Could Help Huntington's Disease Sufferers
Therapeutic strategies to strengthen antioxidant defences could help to prevent the progression of Huntington's Disease. This is the suggestion from the results of the first ever trial on human samples carried out by researchers at the University of Lleida. The results have been published in the latest issue of Free Radical Biology & Medicine magazine.
medicalnewstoday.com

Structure Of Important Neurological Receptor Defined By Scripps Research Scientists
Findings establish a platform to understand G protein-coupled receptors; may help in development of new class of Parkinson's treatments Scientists from The Scripps Research Institute have determined the structure of an adenosine receptor that plays a critical role in a number of important physiological processes including pain, breathing, and heart function.
medicalnewstoday.com

Compounds That Prevent Nerve Damage Discovered By Duke Team
Duke University Medical Center scientists have made a significant finding that could lead to better drugs for several degenerative diseases including Huntington's disease and Alzheimer's disease. Compounds that block the activity of a specific enzyme prevented brain injury and greatly improved survival in fruit flies that had the same disease process found in Huntington's disease.
medicalnewstoday.com

Repligen Announces Publication Of Positive Results With Proprietary HDAC Inhibitor In Huntington's Disease Model
Repligen Corporation (Nasdaq: RGEN) reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington's disease. The study, led by scientists at The Scripps Research Institute, demonstrated that oral administration of the drug candidate to the mice after the onset of symptoms slowed the progression of disease.
medicalnewstoday.com

Pfizer And Medivation Agreement To Co-Develop And Market Dimebon For Alzheimer's And Huntington's Diseases Treatment
Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced today that they have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for treatment of Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer's disease (http://www.connectionstudy.
medicalnewstoday.com

News Tips From The Journal Of Neuroscience
PCP2 Shapes Light Response of ON Bipolar Cells Ying Xu, Pyroja Sulaiman, Rod Feddersen, Jian Liu, Robert G. Smith, and Noga Vardi Activation of G-protein-coupled receptors (e.g., metabotropic glutamate receptors in retinal ON bipolar cells) causes GTP to bind to the G-protein in place of GDP, resulting in dissociation and activation of GÎ± and GÎ²Î³ subunits and subsequent downstream effects (e.g., closing of cation channels).
medicalnewstoday.com

FDA Approves New Huntington's Drug
The US Food and Drug Administration (FDA) announced on Friday that it has approved Prestwick Pharmaceuticals Inc's new drug Xenazine (generic name tetrabenazine) for the treatment of chorea in people with Huntington's disease, heralding the first treatment to receive US approval for any of the disease's symptoms. Huntington's is a rare inherited neurological disorder characterized by chorea or jerky, uncontrolled movements.
medicalnewstoday.com

Statement On FDA's Approval Of XENAZINE(R) For The Treatment Of Chorea Associated With Huntington's Disease
The Hereditary Disease Foundation (HDF) is extremely pleased the U.S. Food and Drug Administration has approved Xenazine, or tetrabenazine, for the treatment of chorea associated with Huntington's disease. "Chorea is a major cause of disability and death in patients with Huntington's disease.
medicalnewstoday.com

Scientists Create Disease-Specific Stem Cell Lines
US researchers have found a way to produce immortal cell strains and tissue types from diseased patients by converting their cells into pluripotent stem cells with the same genetic errors. The new cell lines will enable scientists to investigate ten different genetic disorders like Parkinson's, muscular dystrophy, and type 1 diabetes in the test tube instead of in the patient, a huge step forward compared to current methods.
medicalnewstoday.com

Huntington's Disease: Catching It Early
Huntington's disease normally only begins to cause its tell-tale memory and physical coordination impairments after affected individuals reach the age of 30. The nerve damage that creates these impairments is thought to be partly due to a destructive immune response in the brain. The current study now shows that this inflammatory response starts to brew elsewhere in the body long before it inflicts brain damage.
medicalnewstoday.com

Researchers Link Huntington's Disease To Overactive Immune Response In The Brain
The damage to brain tissue seen in Huntington's disease may be caused by an overactive immune response in the bloodstream and the brain, according to new findings from two teams of researchers at the University of Washington in Seattle and University College London. The findings were published online July 14 in the Journal of Experimental Medicine.
medicalnewstoday.com

Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study In Huntington's Disease
Medivation, Inc. (NASDAQ: MDVN) announced top-line results of a Phase 2 study showing that its investigational drug Dimebon™ significantly improved cognitive function in patients with mild-to-moderate Huntington's disease (HD). Cognitive function was significantly improved over placebo (p=0.03) as measured by the Mini-Mental State Examination (MMSE), the cognition scale most widely used by clinicians to assess patients with neurodegenerative diseases.
medicalnewstoday.com

Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study In Huntington's Disease
Medivation, Inc. (Nasdaq: MDVN) announced top-line results of a Phase 2 study showing that its investigational drug Dimebon(TM) significantly improved cognitive function in patients with mild-to-moderate Huntington's disease (HD). Cognitive function was significantly improved over placebo (p=0.03) as measured by the Mini-Mental State Examination (MMSE), the cognition scale most widely used by clinicians to assess patients with neurodegenerative diseases.
medicalnewstoday.com

A Protein Sequence Associated With Huntington's Disease May Become Life-Saving Vaccine Component
On June 10, 2008 the scientific journal Vaccine published a paper by the Massachusetts based biotech company Cure Lab, Inc., demonstrating that a protein sequence important in neurodegenerative Huntington's disease can be safely used as a new generation of vaccine adjuvants. The major component of every vaccine is an antigen that elicits specific immunity to a particular virus, bacteria or even cancer cells.
medicalnewstoday.com

HUNTINGTONS DISEASE News, Sports, Shopping, Travel information

Huntingtons Disease - Rss Feed Directory